Your browser doesn't support javascript.
loading
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Gleeson, Mary; Counsell, Nicholas; Cunningham, David; Lawrie, Anthony; Clifton-Hadley, Laura; Hawkes, Eliza; McMillan, Andrew; Ardeshna, Kirit M; Burton, Cathy; Chadwick, Nick; Gambell, Joanna; Smith, Paul; Mouncey, Paul; Pocock, Christopher; Radford, John; Davies, John; Turner, Deborah; Kruger, Anton; Johnson, Peter; Linch, David.
Afiliación
  • Gleeson M; The Royal Marsden Hospital, London and Surrey, London, UK.
  • Counsell N; Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Cunningham D; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
  • Lawrie A; The Royal Marsden Hospital, London and Surrey, London, UK.
  • Clifton-Hadley L; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
  • Hawkes E; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
  • McMillan A; Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Melbourne, Australia.
  • Ardeshna KM; Eastern Health, Melbourne, Australia.
  • Burton C; Nottingham City Hospital, Nottingham, UK.
  • Chadwick N; University College London, London, UK.
  • Gambell J; Mount Vernon Cancer Centre, Northwood, UK.
  • Smith P; HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Mouncey P; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
  • Pocock C; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
  • Radford J; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
  • Davies J; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
  • Turner D; East Kent Hospitals, Canterbury, UK.
  • Kruger A; The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Johnson P; Western General Hospital, Edinburgh, UK.
  • Linch D; Torbay Hospital, Torquay, UK.
Br J Haematol ; 192(6): 1015-1019, 2021 03.
Article en En | MEDLINE | ID: mdl-32436212
ABSTRACT
We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Español de Linfomas/Transplante de Médula Ósea (GELTAMO)-IPI, where baseline ß2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso / Rituximab Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Br J Haematol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso / Rituximab Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Br J Haematol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido